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Syntheses and Cellular Investigations of 173-, 152- and 131-Amino
Acid Derivatives of Chlorin e61
R. G. Waruna Jinadasa, Xiaoke Hu, M. Graça H. Vicente, and Kevin M. Smith*
Louisiana State University, Department of Chemistry, Baton Rouge LA, 70803, USA.

Abstract
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A series of amino acid conjugates of chlorin e6, containing lysine or aspartic acid residues in
positions 173, 152 or 131 of the macrocycle were synthesized and investigated as photosensitizers
for photodynamic therapy of tumors. All three regioisomers were synthesized in good yields and
in 5 steps or less from pheophytin a (1). In vitro investigations using human carcinoma HEp2 cells
show that the 152-lysyl regioisomers accumulate the most within cells, and the most phototoxic
are the 131 regioisomers. The main determinant of biological efficacy appears to be the
conjugation site, probably because of molecular conformation. Molecular modeling investigations
reveal that the 173-substituted chlorin e6 conjugates are L-shaped, the 152 and 131 regioisomers
assume extended conformations, and the 131 derivatives are nearly linear. It is hypothesized that
the 131-aspartylchlorin e6 conjugate may be a more efficient photosensitizer for PDT than the
commercial currently used 152 derivative.

Introduction
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Photodynamic therapy (PDT) is a binary cancer therapy that relies on the selective uptake of
a photosensitizer into cancer cells followed by irradiation with red light, which produces
singlet oxygen and other reactive oxygen species.1–4 Highly cytotoxic singlet oxygen readily
reacts with electron-rich biomolecules in its vicinity, such as unsaturated lipids, amino acids
and DNA.5 Due to the known limited diffusion of singlet oxygen through tissues the PDT
effects are largely localized to the photosensitizer-containing cells, thus reducing potential
damage to normal cells in the vicinity of the tumor. The selectivity of the PDT treatment
depends both on the tumor-targeting ability of the photosensitizer and the light used to
activate it. An ideal photosensitizer should have minimal toxicity in the dark, a high
quantum yield of triplet state formation in the presence of light, high selectivity for tumor
cells over normal cells, rapid clearance from normal tissues, and a strong absorption peak
within the “therapeutic window” (600–800 nm) for optimal light penetration through tissue.
Commercial hematoporphyrin derivative is a porphyrin-based photosensitizer that has been
commercially developed and approved in several countries for the PDT treatment of
melanoma, early and advanced stage cancer of the lung, digestive tract, genitourinary tract
1Abbreviations: PS, photosensitizer; PDT, photodynamic therapy; DMF, dimethylformamide; DMSO, dimethylsulfoxide; THF,
tetrahydrofuran; DME, dimethyl ester; TME, trimethyl ester; DBU, 1,8-diazabicyclo[5.4.0]undec-7-ene; DCC, 1,3dicyclohexylcarbodiimide; TFA, trifluoroactic acid; DIEA, N,N-diisopropylethylamine; TBTU, 2-(1H-benzotriazole-1-yl)-1,1,3,3tetramethyluronium tetrafluoroborate; DMAP, 4-dimethylaminopyridine; HOBt, 1-hydroxybenzotriazole; PBS, phosphate buffered
saline; FBS, fetal bovine serum; MEM, modified eagle medium; ER, endoplasmic reticulum.
*
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Supporting Information Available: Normalized absorption spectra, energy minimized conformations in water, time-dependent
uptake, and subcellular localization microscopy figures (S1–S10). Proton NMR spectra for compounds 2–13 and other synthetic
intermediates, carbon- 13 NMR shifts, carbon-13 NMR spectra (21 pages). This material is available free of charge via the internet at
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and Barret’s esophagus.3–6 However, it has only a weak absorption within the therapeutic
window and often induces skin photosensitivity in patients. For these reasons, several
second generation photosensitizers bearing stronger and red-shifted absorption within the
therapeutic window have been investigated in PDT; these include tetra(metahydroxyphenyl)chlorin, (mTHPC), HPPH 2-[1-hexyloxyethyl]-2-devinylpyropheophorbide
a (HPPH), lutetium(III) texaphyrin (LuTex), mono-L-aspartylchlorin e6, and phthalocyanine
4 (Pc4).3–6 Chlorins (dihydroporphyrins) are particularly promising photosensitizers for
PDT because of their intense absorptions above 640 nm; in particular chlorophyll a
derivatives are inherently amphiphilic macrocycles that have been extensively investigated
and shown to have low dark toxicities while being able to effectively generate singlet
oxygen upon light activation.7–9 Among these, HPPH and mono-L-aspartylchlorin e6 have
been extensively investigated and are currently in advanced-stage clinical trials for
oncologic PDT applications;10–13 both of these chlorophyll a based compounds have shown
superior PDT activity as well as rapid clearance from normal tissue and decreased patient
photosensitivity compared with commercial hematoporphyrin derivative.
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Chlorophyll a derivatives of the chlorin e6 series possess three carboxylic side chains that
can be derivatized in multiple ways to produce novel amphiphilic photosensitizers for PDT
investigations. For example, their conjugation to peptides, sugars, lipoproteins and
polyamines have been reported.14–19 In particular, amino acid residues have been found to
improve the biological effects of porphyrin-based compounds, and their nature and position
about the macrocycle can have a significant impact on PDT efficacy.5,20,21 In the present
study we synthesized and investigated 173, 152 and 131 amino acid-conjugates of chlorin e6
(Figure 1), to evaluate the effect of the nature, conjugation site and position of the amino
acid on the PDT efficacy of the conjugates in vitro, using human carcinoma HEp2 cells. The
structure of mono-L-aspartylchlorin e6, bearing the aspartyl residue in position 152 (rather
than in 173 as initially proposed) has recently been established.22 This study led us to design
new syntheses of the 173 and 131 aspartyl regioisomers of mono-L-aspartylchlorin e6, as
well as investigate the corresponding cationic lysine derivatives, which could potentially
show stronger interactions with negatively charged biological molecules and plasma
membranes, and consequently enhanced PDT efficacy.23 Furthermore, we investigated the
introduction of a spacer group, ethylene diamine, and of metalation, via insertion of
palladium(II). The photosensitizing properties of porphyrin derivatives are known to be
modulated by inner coordinated metal ions and associated axial ligands.24–26 In particular,
Pd(II)-complexes have been shown to be efficient generators of singlet oxygen, and the
palladium(II)-bacteriopheophorbide is currently being evaluated in clinical trials for the
treatment of prostate cancer.27,28 The work described herein indicates that the site of amino
acid conjugation, rather than the presence of Pd(II) and even the nature of amino acid, is the
major determinant of phototoxicity.

Results and Discussion
1. Syntheses
The synthetic route to the 173-lysyl conjugate of chlorin e6 (3) is shown in Scheme 1.
Pheophytin a (1) was obtained by extraction from Spirulina pacifica alga, an ideal source for
chlorophyll a because of the complete absence of chlorophyll b. The selective hydrolysis of
the phytyl ester group of pheophytin a (1) using aqueous TFA produced pheophorbide a in
high yield, without affecting the β-keto ester of the isocyclic ring.29 This ring serves as a
natural protecting group for the 131- and 152-positions during the coupling reactions.
Selective hydrolysis of the phytyl ester produced a free 173-carboxylic acid group which
was activated with DCC/DMAP and coupled with H-lysine (OtBu) methyl ester to form the
lysine (OtBu) methyl ester pheophorbide a (2) in 52% yield.32 1H NMR spectroscopy
demonstrated the existence of the isocyclic ring and new peaks for the lysine residue.
J Med Chem. Author manuscript; available in PMC 2012 November 10.
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Subsequent isocyclic ring-opening with sodium methoxide31 in THF produced the 173lysyl(Boc) chlorin e6 TME in high yield (89%); deprotection of the amine group of the
lysine side chain with TFA in CH2Cl2 followed, and yielded the 173-lysylchlorin e6 (3) in
30% overall yield from pheophytin a (1).
In order to synthesize the 152 and 131 amino acid derivatives of chlorin e6, pheophytin a (1)
was converted into methyl pheophorbide a (4) by transesterification of the ester group using
sulfuric acid in methanol, as previously reported,31 followed by isocyclic ring-opening, as
shown in Scheme 1. An optimized yield of 98% of chlorin e6 trimethyl ester was obtained
when 1.1 equiv of freshly prepared sodium methoxide in THF were used in the ring-opening
reaction. Chlorin e6 (5) was obtained by hydrolysis of the three methyl esters using an
excess of LiI in ethyl acetate under reflux conditions for 24 hours.33 Alternative hydrolysis
under basic conditions using NaOH and LiOH gave lower yields of chlorin e6. Under acidic
conditions the 131-carboxylic acid of chlorin e6 is deactivated34 allowing for the selective
methylation of the 152-and 173-carboxylic acids with 5% H2SO4/MeOH to give chlorin e6
dimethyl ester (6) in quantitative yield.22 Chorin e6 (5) was used as starting material for the
preparation of the 152 amino acid derivatives of chlorin e6 (as shown in Scheme 2), whereas
the chlorin (6) and methyl pheophorbide a (4) were used to prepare the 131 amino acid
derivatives of chlorin e6 (as shown in Schemes 3 and 4).
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We have previously shown22 that the 152-carboxylic acid of chlorin e6 is the most reactive,
regardless of the coupling reagent employed. Therefore, upon activation of chlorin e6 (5)
with one equiv of DCC/DMAP, followed by addition of protected amino acid, reaction with
diazomethane35 and deprotection under acidic conditions, the 152-aspartyl (7a) and -lysyl
(7b) derivatives of chlorin e6 were obtained in overall 36% and 56% yields, respectively
(Scheme 2). The use of excess DCC significantly reduced the yields obtained due to the
formation of the 173,152-di-amino acid conjugate as a side product.
Insertion of palladium into the chlorin ring was attempted before the deprotection step to
simplify the purification process; however low yields of the target metallochlorins were
obtained. Therefore, palladium insertion was performed after deprotection, using either
palladium(II) acetate or palladium(II) chloride. Quantitative yields for the metal insertion
reaction were obtained using 1.2 equiv of palladium(II) acetate in THF at 40 °C, to produce
the corresponding Pd(II) complexes (8). As expected, significant blue shifts in the UV-Vis
spectrum along with 1H NMR and mass spectrometry confirmed the insertion of palladium.
Heavy metal atoms in the core of the tetrapyrroles have been shown to facilitate intersystem
crossing and increase the production of singlet oxygen due to the inner heavy atom
effect.36,37
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Two routes were used to synthesize the 131-amino acid conjugates: (1) Selective
esterification of 173- and 152- carboxylic acids of chlorin e6 to produce the monocarboxylic
acid (6) followed by coupling34 (Scheme 3), and (2) isocyclic ring-opening of methyl
pheoporbide a (4) with a nucleophile (Scheme 4). The 131−carboxylic acid of chlorin (6)
was activated using HOBt/TBTU under basic conditions38 and coupled with L-aspartic
di(tert)butyl ester. With DCC/DMAP a lower yield was obtained for the coupling reaction.
Subsequent deprotection of both carboxylic acids in the aspartic chain provided (9) in 57%
overall yield from chlorin e6 (Scheme 3). Coupling of the 131−carboxylic acid of chlorin (6)
with β-alanine tert-butyl ester followed by deprotection using TFA gave the 131-βalanylchlorin e6 dimethyl ester (10) in 64% overall yield. Aspartic di(tert)butyl ester was
then coupled under similar conditions, followed by removal of the tert-butyl protecting
group to give (11) in 54% yield from (10). β-Alanine provides a 4-atom link between the
aspartic acid and chlorin e6 dimethyl ester and allows for direct comparison with the lysine
derivative 13 (see Scheme 4). The use of a linker significantly increased the yield of the

J Med Chem. Author manuscript; available in PMC 2012 November 10.
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coupling reaction (from 66 to 87%) and it can also affect the biological properties of the
photosensitizer.20,39
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The nucleophilic ring-opening of the isocyclic ring in pheophorbide a with ethylenediamine
and ethanolamine has already been previously reported.25,40 We took advantage of this high
yielding isocyclic ring-opening reaction to develop a potentially high yielding synthetic
route to novel chlorin e6 photosensitizers, directly from pheophytin a (1) in four steps.
Nucleophilic ring-opening of the isocyclic ring with ethylenediamine produced molecule
(12) in 91% yield. Subsequent coupling with protected lysine followed by deprotection gave
the desired product (13) in four steps and in 55% overall yield from pheophytin a (1). No
absorption quenching of the chlorin macrocycle was observed upon conjugation with the
amino acid lysine in comparison with the apsrtic acid derivative (see Figure S1 of the
Supporting Information).
2. Molecular Modeling
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Conformation analyses for 173-, 152- and 131-lysylchlorin e6 derivatives 3, 7b and 13 were
performed in both the gas phase and in water at the HF/6-31G level. These calculations were
based on the atom coordinates from the X-ray structure of 152-aspartylchlorin e6 tetramethyl
ester.22 The minimum energy conformations found for compounds 3, 7b and 13 in the gas
phase, shown in Figure 2a–c, respectively, were very similar to those found in water phase
(Figure S2 of the Supporting Information). In addition, the conformation of a mono-cationic
131-lysylchlorin e6 derivative without a linker was also investigated in the gas phase (Figure
2d). As expected, the lysine residue in the 173-lysyl derivative 3 is nearly perpendicular to
the macrocyclic plane (Figure 2a), while in the 152-lysyl derivative 7b it forms
approximately a 120° angle (Figure 2b). On the other hand the lysine residue extends away
from the macrocycle in the 131-lysyl derivatives, with and without the short spacer (Figures
2c,d). Consequently, in the L-shape conformation of the 173-lysylchlorin e6 derivative, the
amino acid shelters one face of the chlorin ring, while in the case of the 152- and 131-lysyl
derivatives, it extends away from the macrocycle resulting in a nearly linear conformation
for the 131 derivatives. The use of a short linker and the presence of two (rather than one)
positive charges, as a result from conjugation to the C-terminus rather than the N-terminus
of the amino acid, do not appear to have a significant effect upon the preferred
conformation; the main determinant of molecule conformation is the site of substitution.
While the minimum energy conformations found in water were similar to those in the gas
phase, it is possible that in water intermolecular forces (such as π-π stacking) predominate
over the intramolecular interactions, in particular for the linear 131-lysylchlorin e6
derivatives.

NIH-PA Author Manuscript

3. Cell Culture Studies
3.1. Time-dependent Cellular Uptake—The results obtained for the time-dependent
uptake of chlorin e6 and its derivatives at a concentration of 10 µM in human HEp2 cells are
shown in Figure 3 (also see Figure S3 of the Supporting Information). All amino acid
conjugates of chlorin e6 were readily taken up by cells and showed uptake kinetics similar to
those of unconjugated chlorin e6. Interestingly, the 152-lysylchlorin e6 derivatives 7b and its
palladium(II) complex 8b accumulated to a much higher extent than all other compounds, at
all time points studied. In comparison with chlorin e6, the lysyl derivatives 7b and 8b
showed 18-fold and 4-fold higher cellular uptake, respectively, after 24 h. The observed
high uptake for derivatives 7b and 8b is probably due to the lysine residue in position 152
since the corresponding aspartyl derivatives 7a and 8a accumulated to a significantly lower
extent within cells. Presumably, the stronger interactions between the positively charged
lysine derivatives (compared with the corresponding aspartyl derivatives), with the
negatively charged plasma membrane leads to enhanced cellular uptake.20,23 On the other

J Med Chem. Author manuscript; available in PMC 2012 November 10.
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hand a lysine residue in position 173, as in derivative 3, showed a dramatic decrease in
cellular uptake compared with the same residue at position 152, suggesting that the molecule
conformation plays an important role on the mechanism of cellular uptake. Indeed the
extended conformation of the 152-lysylchlorin e6 derivative 7b (Figure 2b) might be the
most favored for penetration across the plasma membrane, compared with the L-shape and
linear conformations of the 173- and 131-lysyl derivatives (Figures 2a,c), respectively. The
presence of a chelated palladium ion, as well as the more linear structure of the 131-lysyl
substituent might lead to enhanced π-π stacking of the macrocycles, thereby decreasing
cellular uptake.

NIH-PA Author Manuscript

3.2. Cytotoxicity—The dark cytotoxicity and phototoxicity of chlorin e6 and its
derivatives was evaluated in HEp2 cells exposed to increasing concentrations of each
compound up to 400 µM; the results are shown in Figures 4 and 5, respectively, and are
summarized in Table 1. Chlorin e6 and its lysyl derivatives 3, 7b and 8b were found to be
non-toxic in the dark up to the highest concentration (400 µM) investigated. All other amino
acid derivatives showed very low dark cytotoxicities, with IC50 > 320 µM except for the
131-chlorin e6 derivatives 9 and 13, which showed IC50 of 285 and 268 µM, respectively.
However, upon exposure to a low light dose (1 J/cm2), all chlorin e6 derivatives were found
to be highly toxic to HEp2 cells (Figure 3). The most phototoxic were the 131-chlorin e6
derivatives 9, 11 and 13, with estimated IC50 values of 0.61, 0.82 and 1.34 µM, respectively.
Among these, the most promising aspartyl derivatives for PDT applications are compounds
9 and 11, because they have the highest dark cytotoxicity/phototoxicity ratio, > 466:1. The
presence of the β-alanine spacer between the 131 carbonyl group and the aspartic acid
residue seems to have only a small effect, slightly decreasing compound cytotoxicity. On the
other hand the 152-aspartylchlorin e6 derivative 7a was less phototoxic than its 131
regioisomer 9 by approximately 7-fold, and the introduction of palladium(II) further reduced
its phototoxicity. The positively charged 173- and 152-lysylchlorin e6 derivatives 3 and 7b
were the least phototoxic, and the introduction of palladium increased the phototoxicity of
the 152 derivative by about 10-fold. These results show for the first time that the
phototoxicity of amphiphilic conjugates of chlorin e6 depends mainly on the site of
conjugation, probably as a result of its effect on molecular conformation; the nature of the
amino acid, the molecule overall charge, and the presence of palladium(II) also affect
phototoxicity, but apparently to a smaller extent. Our results suggest that the most extended,
nearly linear conformation of the 131 regioisomers facilitates binding to specific biological
substrates, enhancing their toxic effect.
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3.3. Intracellular Localization—The preferential sites of subcellular localization of this
series of chlorin e6 derivatives were evaluated by fluorescence microscopy, upon exposure
of HEp2 cells to 10 µM compound concentrations for 18 h. Figure S4 of the Supporting
Information shows the fluorescence pattern observed for all compounds and Table 2
summarizes their main sites of subcellular localization. Overlay experiments using the
organelle specific fluorescence probes BoDIPY Ceramide (Golgi), LysoSensor Green
(Lysosomes), MitoTracker Green (mitochondria), and ER tracker Blue/White fluorescence
(ER) were conducted to evaluate the preferential sites of compound localization, as seen in
Figures 6, 7 and 8 for the most phototoxic 131-regioisomers, respectively, and Figures S5–
S10 of the Supporting Information. All chlorin e6 derivatives 3, 7a, 7b, 8a, 8b, 9, 11 and 13
were found to localize in the lysosomes and the ER (Table 2). This is not surprising, since
the structurally-related 152-aspartylchlorin e6 is a known lysosomal localizer, and HPPH (2[1-hexyloxyethyl]-2-devinylpyropheophorbide a) localizes preferentially in the ER.41
Photodamage to ER and/or lysosomes has been shown to lead to activation of apoptotic
pathways.41–43 Furthermore, all the 131-chlorin e6 regioisomers 9, 11 and 13 were also
found in Golgi, and in addition the most phototoxic derivative 9 also localized in

J Med Chem. Author manuscript; available in PMC 2012 November 10.
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mitochondria; presumably, the photodamage effect to multiple organelles caused by the 131
derivatives can trigger various apoptotic pathways, leading to more effective cell
destruction. The multiple sites of intracellular localization observed for the 131-chlorin e6
derivatives might again be due to their linear conformations that facilitate their binding to
various intracellular sites.

Conclusions
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A series of eight chlorin e6 derivatives, conjugated with either aspartic acid or lysine
residues at positions 173, 152 or 131 of the chlorin macrocycle have been synthesized in
good yields from pheophytin a (1). In comparison with chlorin e6 (5), all amino acid
derivatives readily accumulated within human HEp2 cells, and in particular the 152-lysyl
derivatives were taken up by cells to a significantly higher extent than were all other
regioisomers. On the other hand, the metal-free 152-lysylchlorin e6 derivative (7b) showed
the least phototoxicity, followed by the 173-lysyl regioisomer (3); insertion of palladium
into 152-lysychlorin e6 (7b) increased toxicity by approximately 10-fold. However, the most
phototoxic compounds were found to be the 131−regioisomers, bearing either an aspartic
acid or a lysine residue directly conjugated to position-13 of the chlorin macrocycle, or
connected via a β-alanine or ethylene diamine spacer. The most phototoxic compound of
this series, and the most promising for PDT applications, is 131-aspartylchlorin e6 (9).
Molecular modeling calculations show that the 131-regioisomers assume extended, nearly
linear conformations that might facilitate their binding to multiple intracellular components,
and subsequent photodamage to multiple cellular sites. Therefore, the site of amino acid
conjugation at the chlorin e6 macrocycle is a major determinant of compound phototoxicity,
and we hypothesize that the 131-regioisomer of mono-L-aspartylchlorin e6 (9) might be a
more efficient photosensitizer for PDT than is the commercial regioisomer (152-mono-Laspartylchlorin e6).

Experimental Section
1. Chemistry
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All air and moisture sensitive reactions were performed in dried and distilled solvents under
an argon atmosphere. All solvents and reagents were purchased from commercial sources,
unless otherwise stated. Silica gel 60 (230×400 mesh, Sorbent Technologies) was used for
column chromatography. Analytical thin-layer chromatography (TLC) was carried out using
polyester backed TLC plates 254 (precoated, 200 µm) from Sorbent Technologies. NMR
spectra were recorded on an AV-400 spectrometer (400 MHz for 1H, 100 MHz for 13C). The
chemical shifts are reported in δ ppm using the following partially deuterated solvents as
internal references: CD2Cl2 5.32 ppm (1H), 54 ppm (13C); d-DMSO 2.49 ppm (1H), 39.5
ppm (13C); d-CH3OH 4.78 ppm (1H), 49.0 ppm (13C); CDCl3 7.26 ppm (1H), 77.16 ppm
(13C); (CH3)2CO 2.50 ppm (1H), 29.84 ppm (13C). Electronic absorption spectra were
measured on an Agilent 8453 UV/Vis spectrophotometer. Mass spectra were obtained on a
Bruker Omniflex MALDI Time-of-Flight Mass Spectrometer. Spirulina pacifica alga was
purchased as a spray-dried powder from Cyanotech, Hawaii. Pheophytin a (1) was extracted
from Spirulina pacifica alga as previously published and its spectroscopic characterization
agreed with the published data.29 All compounds synthesized were purified and isolated in ≥
95% purity, as evidenced by analytical TLC in at least two solvent systems, and confirmed
by the absence of extraneous tetrapyrrole resonances in 1H- and 13C-NMR spectra. Energy
minimization of all compounds was performed in the framework of Hartree Fock. The
restricted-Hartree Fock functional was used at the 6-31G level. All structures were
optimized without any symmetry constrains. The solvent effects were accounted for using
the Polarizable Continuum Model (PCM). All calculations were performed using the
Gaussian 09 program package.
J Med Chem. Author manuscript; available in PMC 2012 November 10.
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173-Lysyl(Boc)OMe-pheophorbide a (2)—Pheophytin a (1) (250 mg, 0.29 mmol) was
selectively hydrolyzed to the 173 carboxylic acid without affecting the 131 carbomethoxy
group, as previously reported.31 After evaporation of solvent, 155 mg (0.26 mmol), 90% of
pheophorbide a (C35H36N4O5) was obtained. The spectroscopic data obtained for the
compound agreed with published data. Pheophorbide a, (100 mg; 0.169 mmol) was
dissolved in 10 ml of CH2Cl2. Then DCC (42 mg) and DMAP (10 mg) were added and left
it for 15 min. H-Lys(Boc)OMe•HCl (60 mg) and DIEA (0.035 ml) were dissolved in 5 ml of
CH2Cl2, added to the reaction mixture and stirred for 4 h. [Note: this reaction is favored by
dilute conditions; concentrated conditions favor the formation of the anhydride
(bispheophorbide), and will slow the reaction]. The reaction mixture was washed with 10%
citric acid, water and brine, dried over anhydrous Na2SO4and purified on a silica gel column
(10% acetone in CH2Cl2). After the major brown band was eluted from the column, the
solvent was evaporated and the solid was dissolved in ethyl acetate and filtered (DCC
precipitated in ethyl acetate.) Evaporation of the filtered ethyl acetate gave 74 mg, 0.089
mmol, 52% yield of lysyl(Boc)OMe-pheophorbide a (C47H58N6O8), 1H NMR [(CD3)2CO,
400 MHz]: δ 9.12 (s, 1H), 8.71 (s, 1H), 8.70 (s, 1H), 7.64 (dd, J = 17.8, 11.63 Hz, 1H), 7.20
(d, J = 7.2 Hz, 1H), 6.33 (s, 1H), 6.02 (d, J = 17.85 Hz, 1H), 5.93 (d, J = 11.61 Hz, 1H),
5.77 (s, 1H), 4.65 (m, 1H), 4.41 (m, 1H), 4.21 (m, 1H), 3.91 (s, 3H), 3.59 (s, 3H), 3.47 (s,
3H), 3.19 (s, 3H) 3.09 (q, J = 7.5 Hz, 2H), 2.92 (3H, s), 2.83 (m, 2H), 2.66 (m, 1H), 2.48 (m,
1H), 2.25 (m, 1H), 1.85-1.62 (br, 4H), 1.86 (d, J = 7.24, 3H), 1.37 (t, J = 7.58, 3H), 1.43 (m,
2H), 1.26 (s, 9H), − 1.95 (s, 1H), −2.23 (s, 1H).
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173-Lysyl-chlorin e6 TME (3)—Compound 2 (74 mg, 0.089 mmol) was dissolved in dry
2:1 THF/MeOH (10 ml) and stirred under argon for 10 min. Sodium methoxide (0.17 mL of
a 0.5 M solution) was added and the reaction was allowed to stir at 0 °C for 1 h. The
reaction was followed using spectrophotometry. The solution turned from brown to green as
the isocyclic ring opens. The reaction mixture was then poured into water. The mixture was
extracted with CH2Cl2 and the organic layer was washed with water and 5% citric acid,
dried over anhydrous Na2SO4 and then evaporated. The residue was dissolved in 2%
MeOH/CH2Cl2 and purified on a silica gel plug with the same mobile phase. The solvent
was evaporated and 68 mg (0.078 mmol), 89% yield of 173-lysyl(Boc)chlorin e6 TME
(C48H62N6O9) was obtained. 1H NMR [(CD3)2CO, 400 MHz]: δ 9.80 (s, 1H), 9.65 (s, 1H),
9.03 (s, 1H), 8.19 (dd, J = 17.87, 11.58 Hz, 1H), 7.44 (d, J = 7.6 Hz, 1H), 6.40 (d, J = 17.87,
1.33 Hz, 1H), 6.13 (d, J = 11.61, 1.36 Hz, 1H), 5.89 (s, 1H), 5.38 (m, 2H), 4.63 (q, J = 7.22
Hz, 1H), 4.55 (dd, J = 10.34, 1.95 Hz, 1H), 4.44 (m, 1H), 4.25 (s, 3H), 3.78 (q, J =7.67, 2H)
3.75 (s, 3H), 3.69 (s, 3H), 3.56 (s, 3H) 3.49 (s, 3H), 3.27 (3H, s), 3.00 (m, 2H), 2.66 (m,
1H), 2.33 (m, 1H), 2.20 (m, 1H), 1.85-1.62 (br, 4H), 1.78 (d, J = 7.24, 3H), 1.69 (t, J = 7.58,
3H), 1.43 (m, 2H), 1.32 (s, 9H), − 1.32 (s, 1H), −1.52 (s, 1H). Lysyl(Boc)chlorin e6 TME
(68mg, 0.078 mmol) was dissolved in 2 ml of dry CH2Cl2 in an ice bath under argon.
Thioanisole (0.057 mmol) and 1 ml of TFA were added and the reaction mixture was
allowed to stir overnight. The reaction mixture was evaporated several times with diethyl
ether to remove TFA. The resulting precipitate was washed several times with diethyl ether
to remove thioanisole. The precipitate was dissolved in CH2Cl2 and washed three times with
H2O and once with 10% NaHCO3 to remove last traces of TFA. The organic layer was dried
over anhydrous Na2SO4. Solvent was evaporated and 43 mg (0.056 mmol), 72% yield of
173-lysylchlorin e6 TME (C43H54N6O7) was obtained. UV-Vis (acetone): λmax (ε/M−1cm−1)
664 (65,000), 608 (4871), 528 (4461), 500 (16,100), 400 (213,000); 1H NMR [(CD3)2CO,
400 MHz]: δ 9.79 (s, 1H), 9.63 (s, 1H), 9.03 (s, 1H), 8.17 (dd, J = 17.87, 11.58 Hz, 1H),
7.59 ( d, J = 7.6 Hz, 1H), 6.38 (d, J = 17.87, 1.33 Hz, 1H), 6.12 (d, J = 11.61, 1.36 Hz, 1H),
5.37 (m, 2H), 4.63 (q, J = 7.22 Hz, 1H), 4.55 (dd, J = 10.34, 1.95 Hz, 1H), 4.44 (m, 1H),
4.25 (s, 3H), 3.76 (m, 2H) 3.75 (s, 3H), 3.69 (s, 3H), 3.55 (s, 3H) 3.48 (s, 3H), 3.25 (3H, s),
3.09 (m, 2H), 2.67 (m, 1H), 2.30 (m, 1H), 2.20 (m, 1H), 1.85-1.62 (br, 3H), 1.78 (d, J =
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7.24, 3H), 1.68 (t, J = 7.58, 3H), 1.51 (m, 2H), 1.39 (m, 2H), − 1.33 (s, 1H), −1.53 (s, 1H).
HRMS (MALDI-TOF) m/z 767.442 [M+H]+, calcd. for C43H55N6O7 767.413.

NIH-PA Author Manuscript

Chlorin e6 (5)—Chlorin e6 TME was prepared as previously published and its
spectroscopic characterization agreed fully with the published data.22 Chlorin e6 TME (50
mg, 0.078 mmol) was dissolved in anhydrous ethyl acetate (10 ml) under argon. Lithium
iodide (124 mg, 0.94 mmol) was added. The reaction mixture was refluxed for 48 h under
argon. The reaction mixture was diluted with water and adjusted to pH 3 with aqueous citric
acid and then washed with CH2Cl2. The solution was evaporated, re-dissolved in acetone
and evaporated several times. The solid was washed with water and then dried under
vacuum. The residue was dissolved in methanol and purified on a Sephadex LH-20 column
to yield 10 mg, 0.017 mmol, 21% yield of chlorin e6 (C34H36N4O6). UV-Vis (MeOH): λmax
(ε/M−1cm−1) 666 (45,271), 610 (8,706), 558 (7,835), 530 (9,721), 502 (15,525), 402
(145,100); MS MALDI: m/z 597 (M + H)+; 1H NMR [(CD3)2CO, 400 MHz]: δ 9.73 (s, 1H),
9.51 (s, 1H), 9.04(s, 1H), 8.05 (dd, J = 17.86, 11.61 Hz, 1H), 6.28 (dd, J = 17.85, 1.26 Hz,
1H), 6.02 (dd, J = 11.57, 1.37 Hz, 1H), 5.60 (d, J = 18.94 Hz, 1H), 5.40 (d, J = 18.94 Hz,
1H), 4.65 (m, 1H), 4.55 (m, 1H), 3.64 (m, 2H), 3.63 (s, 3H), 3.42 (s, 3H), 3.15 (s, 3H), 2.72
(m, 1H), 2.35 (m, 1H), 2.26 (m, 1H), 2.06 (m, 1H), 1.75 (d, J = 7.5 Hz, 3H), 1.64 (t, J = 7.5
Hz, 3H), −1.6 (s, 2H)

NIH-PA Author Manuscript

Chlorin e6 DME (6)—Chlorin e6 DME was prepared as previously published and its
spectroscopic characterization agreed with the published data.22

NIH-PA Author Manuscript

152-Aspartylchlorin e6 DME (7a)—Chlorin e6 (100 mg, 0.168 mmol) was dissolved in
dry CH2Cl2. DCC (35 mg) and DMAP (9 mg) were added and allowed to stir until
completely dissolved. After 3 h, H-Asp(OtBu)2•HCl (47.2 mg) and DIEA (0.029 ml) were
mixed in CH2Cl2 and added to the reaction mixture. The reaction was allowed to stir
overnight. The mixture was diluted with CH2Cl2 and then washed with 5% aqueous citric
acid, followed by washing with brine and water. It was dried over anhydrous Na2SO4 and
then evaporated. The residue was dissolved in CH2Cl2 and treated with ethereal
diazomethane. The residue was dissolved in 2% MeOH/CH2Cl2 and purified via silica gel
column chromatography using the same mobile phase to afford 65 mg, 0.076 mmol; 45%
yield of 152-monoaspartylchlorin e6 di(tert)butyl dimethyl ester (C48H61N5O9). MS
(MALDI) m/z 853 (M + H)+; 1H NMR [(CD3)2CO, 400 MHz]: δ 9.64 (s, 1H), 9.32 (s, 1H),
9.02 (s, 1H), 7.81 (dd, J = 11.58, 17.85 Hz, 1H), 7.00 (s, 1H), 6.09 (dd, J = 17.87, 1.26 Hz,
1H), 5.85 (dd, J = 11.60, 1.29 Hz, 1H), 5.38 (s, 2H), 4.6 (br, 3H), 4.32 (s, 3H), 3.62 (s, 3H),
3.54 (s, 3H), 3.52 (q, J = 7.3 Hz, 2H), 3.30 (s, 3H), 3.02 (s, 3H), 2.78 (m, 3H), 2.44 (m, 2H),
1.87 (m, 1H), 1.65 (d, J = 7.3 Hz, 3H), 1.58 (t, J = 7.7 Hz, 3H), 1.26 (s, 9H), 1.16 (s, 9H),
−1.42 (s, 1H), −1.53 (s, 1H). The 152-Aspartylchlorin e6 di(tert)butyl dimethyl ester (65 mg,
0.076 mmol) was dissolved in 2 ml of dry CH2Cl2 in an ice bath under argon.
Thioanisole(0.006 ml) and 2 ml of TFA were added and the reaction mixture was allowed to
stir overnight. The reaction mixture was evaporated several times with diethyl ether to
remove TFA. The resulting precipitate was washed several times with diethyl ether to
remove thioanisole and then dissolved in CH2Cl2 and washed three times with H2O and
once with 10% NaHCO3 to remove TFA. The organic layer was washed with citric acid
until all precipitate re-dissolved in the organic layer. The organic layer was dried over
anhydrous Na2SO4. Solvent was evaporated and 44 mg, 0.06 mmol; 79% yield of 152aspartylchlorin e6 DME was obtained (C40H45N5O9). UV-Vis (acetone) λmax (ε/M−1cm−1)
664 (48,400), 609 (6,000), 560 (2,000), 529 (6,280), 500 (14,160), 402 (151,800); MS
(MALDI) m/z 841 (M + H)+; 1H NMR [(CD3)2CO, 400 MHz]: δ 9.76 (s, 1H), 9.58 (s, 1H),
9.04 (s, 1H), 8.10 (dd, J = 17.85, 11.59 Hz, 1H), 6.33 (dd, J = 17.87, 0.98 Hz, 1H), 6.07 (dd,
J = 11.61, 1.09 Hz, 1H), 5.32 (m, 2H), 4.84 (m, 1H), 4.60 (m, 2H), 4.26 (s, 3H), 3.72 (q, J =
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7.3 Hz, 2H), 3.57 (s, 3H), 3.54 (s, 3H), 3.45 (s, 3H), 3.21 (m, 3H), 2.95 (dd, J = 16.85, 5.53
Hz, 1H), 2.88 (dd, J = 16.85, 5.09 Hz, 1H) 2.68 (m, 1H) 2.32 (m, 2H), 1.78 (m, 1H), 1.74 (d,
J = 7.3 Hz, 3H), 1.66 (t, J = 7.7 Hz, 3H), −1.39 (s, 1H), −1.58 (s, 1H). HRMS (MALDITOF) m/z 740.376 [M+H]+, calcd. for C40H46N5O9 740.330
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152-Lysylchlorin e6 TME (7b)—Chlorin e6 (75 mg, 0.12 mmol) was dissolved in dry
CH2Cl2 (10 ml). DCC (31.3 mg) and DMAP (11 mg) were added and allowed to stir until
completely dissolved. After 3 h, H-lysyl(Boc)OMe•HCl (45 mg) and DIEA (0.022 ml) were
mixed in CH2Cl2 and added to the reaction mixture. The reaction was allowed to stir
overnight. It was then diluted with CH2Cl2 and washed with 5% aqueous citric acid,
followed by a wash with brine and water. It was dried over anhydrous Na2SO4 and then
evaporated to dryness. The residue it was dissolved in CH2Cl2 and treated with excess
ethereal diazomethane. The residue was dissolved in 12% acetone/CH2Cl2 and purified via
silica gel column chromatography with the same mobile phase to afford 84 mg, 0.097 mmol;
77% yield of 152-lysyl(Boc)chlorin e6 TME (C48H62N6O9). MS (MALDI) m/z 868 (M +
H)+; 1H NMR [(CD3)2CO, 400 MHz]: δ 9.77 (s, 1H), 9.55 (s, 1H), 9.04 (s, 1H), 8.08 (dd, J
= 17.87, 11.58 Hz, 1H), 7.07 (m, 1H), 6.31 (dd, J = 17.87, 1.33 Hz, 1H), 6.06 (dd, J = 11.61,
1.36 Hz, 1H), 5.87 (s, 1H), 5.32 (s, 2H), 4.65 (q, J = 7.22 Hz, 1H), 4.60 (dd, J = 10.34, 1.95
Hz, 1H), 4.49 (m, 1H), 4.26 (s, 3H), 3.71 (q, J = 7.67, 2H) 3.57 (s, 3H), 3.54 (s, 3H), 3.47 (s,
3H) 3.44 (s, 3H), 3.19 (3H, s), 2.97 (m, 2H), 2.71 (m, 1H), 2.37 (m, 2H), 1.80 (m, 3H), 1.77
(d, J = 7.24, 3H), 1.66 (t, J = 7.58, 3H), 1.39 (s, 9H), 1.27 (m, 2H), − 1.35 (s, 1H), −1.56 (s,
1H). The 152-lysyl(Boc)chlorin e6 TME (84 mg 0.097 mmol) was dissolved in 3 ml of dry
CH2Cl2 in an ice bath under argon. Thioanisole (0.01 ml) and 1 ml of TFA were added and
the reaction mixture was allowed to stir overnight. The reaction mixture was evaporated
several times with diethyl ether to remove residual TFA. The resulting precipitate was
washed several times with diethyl ether to remove thioanisole. Then the precipitate was
dissolved in CH2Cl2 and washed three times with H2O and once with 10% NaHCO3 to
remove TFA. The organic layer was washed with citric acid until the precipitate is redissolved in the organic layer. The organic layer was dried over anhydrous Na2SO4 and then
was evaporated to give 56 mg, 0.071 mmol; 73% yield of 152-lysylchlorin e6 TME
(C43H54N6O7). UV-Vis (acetone) λmax (ε/M−1cm−1) 664 (57,800), 608 (4,600), 529 (4,900),
500 (14,800), 400 (187,200); 1H NMR [(CD3)2CO, 400 MHz]: δ 9.68 (s, 1H), 9.42 (s, 1H),
9.02 (s, 1H), 7.95 (dd, J = 17.87, 11.58 Hz, 1H), 7.12 (d, J = 6.8 Hz, 1H), 6.20 (dd, J =
17.87, 1.33 Hz, 1H), 5.95 (dd, J = 11.61, 1.36 Hz, 1H), 5.35 (s, 2H), 4.65 (q, J = 7.22 Hz,
1H), 4.61 (dd, J = 10.34, 1.95 Hz, 1H), 4.53 (m, 1H), 4.27 (s, 3H), 3.59 (m, 2H) 3.55 (s,
6H), 3.48 (s, 3H) 3.37 (s, 3H), 3.09 (3H, s), 2.99 (m, 3H), 2.73 (m, 1H), 2.38 (m, 2H), 1.80
(m, 3H), 1.78 (d, J = 7.24, 3H), 1.61 (t, J = 7.58, 3H), 1.43 (m, 2H), − 1.40 (s, 1H), −1.57 (s,
1H). HRMS (MALDI-TOF) m/z 767.399 [M+H]+, calcd. for C43H55N6O7 767.413
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Palladium(II) 152-Aspartylchlorin e6 DME (8a)—152-Aspartylchlorin e6 DME (44
mg, 0.06 mmol) was dissolved in 2 ml of dry THF. Palladium(II) acetate (14.2 mg, 0.063
mmol) was dissolved in THF and added to the reaction vessel and allowed to stir at 40 °C
for 3 h. The reaction was followed by spectrophotometry. The solution turned from green to
bluish green as the complex formed. After evaporation of solvent, the residue was dissolved
in methanol and purified via Sephadex LH-20 chromatography using the same mobile phase
to afford 50 mg, 0.059 mmol; 98% yield of palladium 152-lysylchlorin e6 TME
(C40H43N5O9Pd). UV-Vis (acetone): λmax (ε/M−1cm−1) 619 (31,240), 579 (6,210), 489
(4,035), 393 (44,160); MS (MALDI) m/z 845 (M + H)+; 1H NMR [(CD3)2CO, 400 MHz]: δ
9.53 (s, 1H), 9.54 (s, 1H), 8.93 (s, 1H), 8.03 (dd, J = 17.82, 11.54 Hz, 1H), 6.17 (d, J =
17.79 Hz, 1H), 6.00 (dd, J = 11.61, 1H), 5.19 (d, J = 18.77 Hz, 1H), 5.04 (d, J = 18.59 Hz,
1H), 4.92 (m, 1H), 4.63 (m, 2H), 4.20 (s, 3H), 3.62 (s, 3H), 3.57 (m, 2H), 3.57 (s, 3H), 3.37
(s, 3H), 3.07 (m, 3H), 2.68 (m, 2H) 2.38 (m, 1H) 2.12 (m, 1H), 1.78 (m, 2H), 1.74 (d, J = 7.3
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Hz, 3H), 1.50 (t, J = 7.7 Hz, 3H). HRMS (MALDI-TOF) m/z 843.109 [M]+, calcd. for
C40H43N5O9Pd 843.210.
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Palladium(II) 152-Lysylchlorin e6 TME (8b)—152-Lysylchlorin e6 TME (56 mg) was
dissolved in 5 ml of dry THF. Palladium(II) acetate (53 mg) was dissolved in THF and
added to the reaction vessel and stirred at 60 °C for 3 h. The reaction was followed by
spectrophotometry. The solution turned from green to bluish green as the complex formed.
After evaporation of solvent, the residue was dissolved in methanol and purified via
Sephadex LH-20 chromatography using the same mobile phase to afford 61 mg, 0.07 mmol;
99% yield of palladium(II) 152-lysylchlorin e6 TME (C43H53N6O7Pd). UV-Vis (acetone):
λmax (ε/M−1cm−1) 620 (97,520), 581 (14,500), 490 (7,600), 394 (140,900); 1H NMR
[(CD3)2CO, 400 MHz] all the peaks were broad due to partial paramagnetic nature of the
compound. HRMS (MALDI-TOF) m/z 872.337 [M+2H]+, 767.450 [M+H-Pd]+ Calcd. for
C43H54N6O7Pd 871.301, C43H55N6O7 767.413.
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131-Aspartylchlorin e6 DME (9)—Chlorin e6 dimethyl ester (55 mg, 0.088 mmol) was
dissolved in dry CH2Cl2. A mixture of HOBt (12 mg), TBTU (29 mg) and DIEA (0.017 ml)
in DMF was added and the mixture was allowed to stir for 30 min. H-Asp(OtBu)2•HCl (60
mg) and DIEA (0.033 ml) were mixed in CH2Cl2 and added to this reaction mixture. The
mixture was stirred overnight. It was diluted with CH2Cl2 and then washed with 5%
aqueous citric acid, followed by a wash with brine and water. It was dried over anhydrous
Na2SO4 and then evaporated. The residue was dissolved in 5% acetone/CH2Cl2 and purified
via silica gel column chromatography using the same mobile phase to afford 50 mg, 0.058
mmol; 66% yield of 131-aspartylchlorin e6 di(tert)butyl dimethyl ester (C48H61N5O9). MS
(MALDI) m/z 852 (M + H)+; 1H NMR [(CD3)2CO, 400 MHz]: δ 9.79 (s, 1H), 9.70 (s, 1H),
9.10 (s, 1H), 8.39 (d, J = 7.93 Hz, 1H), 8.19 (dd, J = 11.58, 17.85 Hz, 1H), 6.37 (dd, J =
17.85, 1.23 Hz, 1H), 6.10 (dd, J = 11.87, 1.26 Hz, 1H), 5.71 (d, J = 18.95 Hz, 1H), 5.30 (m,
2H), 4.67 (q, J = 7.22 Hz, 1H), 4.49 (dd, J = 10.34, 1.95 Hz, 1H), 3.76 (q, J = 7.3 Hz, 2H),
3.74 (s, 3H), 3.64 (s, 3H), 3.61 (s, 3H), 3.50 (s, 3H), 3.27 (s, 3H), 3.16 (dd, J = 5.8, 0.78 Hz,
2H), 2.73 (m, 1H), 2.32 (m, 2H), 1.79 (m, 1H), 1.69 (m, 6H), 1.64 (s, 9H), 1.53 (s, 9H),
−1.57 (s, 1H), −1.85 (s, 1H). The 131-Aspartylchlorin e6 di(tert)butyl dimethyl ester (50 mg,
0.058 mmol) was dissolved in 2 ml of dry CH2Cl2 in a ice bath under argon. Thioanisole
(0.005 ml) and 2 ml of TFA were added and the reaction mixture was stirred overnight. The
reaction mixture was evaporated several times with diethyl ether to remove residual TFA.
The resulting precipitate was washed several times with diethyl ether to remove thioanisole.
Then the precipitate was dissolved in CH2Cl2 and washed three times with H2O and once
with 10% NaHCO3 to remove TFA. The organic layer was dried over anhydrous Na2SO4
and then evaporated to give 38 mg, 0.051 mmol; 88% yield of 131-aspartylchlorin e6 DME
(C40H45N5O9). UV-Vis (acetone): λmax (ε/M−1cm−1) 663 (126,800), 607 (9,000), 528
(7,450), 500 (31,540), 399 (385,800); 1H NMR [(CD3)2CO, 400 MHz]: δ 9.79 (s, 1H), 9.70
(s, 1H), 9.12 (s, 1H), 8.50 (d, J = 7.93 Hz, 1H), 8.19 (dd, J = 11.58, 17.85 Hz, 1H), 6.37 (d,
J = 18.85 Hz, 1H), 6.10 (d, J = 11.87 Hz, 1H), 5.71 (d, J = 18.95 Hz, 1H), 5.45 (dd, J =
13.76, 5.80 Hz, 1H), 5.30 (d, J = 18.93 Hz, 1H), 4.67 (q, J = 7.22 Hz, 1H), 4.50 (dd, J =
10.34, 1.95 Hz, 1H), 3.76 (q, J = 7.3 Hz, 2H), 3.71 (s, 3H), 3.63 (s, 3H), 3.60 (s, 3H), 3.51
(s, 3H), 3.31 (dd, J = 5.76, 3.47 Hz, 2H), 3.26 (s, 3H), 2.70 (m, 2H), 2.31 (m, 2H), 1.79 (m,
1H), 1.71 (d, J = 7.24, 3H), 1.67 (t, J = 7.58, 3H), −1.57 (br s, 1H), −1.87 (s, 1H). HRMS
(MALDI-TOF) m/z 740.344 [M+H]+, Calcd. for C40H46N5O9 740.330
131-β-Alanylchlorin e6 DME (10)—Chlorin e6 DME (55 mg, 0.088 mmol) was
dissolved in dry CH2Cl2. A mixture of HOBt (12 mg), TBTU (29 mg) and DIEA (0.017 ml)
in DMF was added and the mixture was stirred for 30 min. β-Alanyl(OtBu)•HCl (18 mg)
and DIEA (0.017 ml) were mixed in CH2Cl2 and added to the reaction mixture. The mixture

J Med Chem. Author manuscript; available in PMC 2012 November 10.

Waruna Jinadasa et al.

Page 11

NIH-PA Author Manuscript
NIH-PA Author Manuscript

was then allowed to stir for overnight before being diluted with CH2Cl2 and then washed
with 5% aqueous citric acid, followed by a wash with brine and water. It was dried over
anhydrous Na2SO4 and then evaporated to dryness. The residue was dissolved in 5%
acetone/CH2Cl2 and purified via silica gel column chromatography using the same mobile
phase to afford 45 mg, 0.06 mmol; 68% yield of 131- β-alanylchlorin e6 (tert)butyl dimethyl
ester (C43H53N5O7). 1H NMR [(CD3)2CO, 400 MHz]: δ 9.70 (s, 1H), 9.63 (s, 1H), 9.01 (s,
1H), 8.17 (t, J = 5.71 Hz, 1H), 8.11 (dd, J = 11.58, 17.85 Hz, 1H), 6.31 (d, J = 18.85 Hz,
1H), 6.04 (d, J = 11.87 Hz, 1H), 5.65 (d, J = 18.95 Hz, 1H), 5.38 (d, J = 19.06 Hz, 1H), 4.66
(q, J = 7.22 Hz, 1H), 4.52 (dd, J = 10.34, 1.95 Hz, 1H), 4.02 (m, 1H), 3.09 (m, 1H), 3.77 (s,
3H), 3.68 (q, J = 7.3 Hz, 2H), 3.61 (s, 3H), 3.51 (s, 3H), 3.46 (s, 3H), 3.21 (s, 3H), 2.71 (m,
2H), 2.31 (m, 2H), 1.79 (m, 1H), 1.72 (d, J = 7.24, 3H), 1.65 (t, J = 7.58, 3H), 1.54 (s, 9H),
−1.62 (s, 1H), −1.91 (s, 1H). The 131- β-alanylchlorin e6 (tert)butyl dimethyl ester (45 mg,
0.059 mmol) was dissolved in 1.5 ml of dry CH2Cl2 in a ice bath under argon. Thioanisole
(0.005 ml) and 1.5 ml of TFA were added and the reaction mixture was stirred overnight
before being diluted with CH2Cl2 and washed three times with H2O and once with 10%
NaHCO3. The organic layer was dried over anhydrous Na2SO4 and the solvent was
evaporated to give 39 mg, 0.056 mmol; 95% yield of 131- β-alanylchlorin e6 DME
(C39H45N5O7). 1H NMR [(CD3)2CO, 400 MHz]: δ 9.74 (s, 1H), 9.72 (s, 1H), 9.10 (s, 1H),
8.22 (dd, J = 11.58, 17.85 Hz, 1H), 8.15 (t, J = 5.71 Hz, 1H), 6.39 (d, J = 18.85 Hz, 1H),
6.12 (d, J = 11.87 Hz, 1H), 5.65 (d, J = 18.95 Hz, 1H), 5.37 (d, J = 19.06 Hz, 1H), 4.66 (q, J
= 7.22 Hz, 1H), 4.52 (dd, J = 10.34, 1.95 Hz, 1H), 4.07 (m, 1H), 3.95 (m, 1H), 3.77 (s, 3H),
3.68 (q, J = 7.3 Hz, 2H), 3.61 (s, 3H), 3.53 (s, 3H), 3.52 (s, 3H), 3.28 (s, 3H), 2.69 (m, 2H),
2.31 (m, 2H), 1.79 (m, 1H), 1.72 (d, J = 7.24, 3H), 1.65 (t, J = 7.58, 3H), −1.62 (s, 1H),
−1.91 (s, 1H).
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131-β-Alanyl-aspartylchlorin e6 DME (11)—Chlorin e6 DME (39 mg, 0.056 mmol)
was dissolved in dry CH2Cl2. A mixture of HOBt (8 mg), TBTU (18 mg) and DIEA (0.017
ml) in DMF was added and stirred for 30 min. H-Asp(OtBu)2•HCl (40 mg) and DIEA
(0.025 ml) were mixed in CH2Cl2 and added to the reaction mixture. The mixture was
stirred overnight before being diluted with CH2Cl2 and then washed with 5% aqueous citric
acid, followed by a wash with brine and water. It was dried over anhydrous Na2SO4and then
evaporated. The residue was dissolved in 10% acetone/CH2Cl2 and purified via silica gel
column chromatography using the same mobile phase to afford 45 mg, 0.048 mmol; 87%
yield of 131- β-alanyl-aspartylchlorin e6 di(tert)butyl dimethyl ester. 1H NMR [(CD3)2CO,
400 MHz]: δ 9.74 (s, 1H), 9.70 (s, 1H), 9.10 (s, 1H), 8.19 (dd, J = 11.58, 17.85 Hz, 1H),
8.11 (t, J = 5.66 Hz, 1H), 7.64 (d, J = 8.11 Hz, 1H), 6.37 (d, J = 19.18 Hz, 1H), 6.10 (d, J =
12.94 Hz, 1H), 5.66 (d, J = 19.03 Hz, 1H), 5.38 (d, J = 19.09 Hz, 1H), 4.77 (dt, J = 8.14,
5.74 Hz, 1H), 4.66 (q, J = 7.22 Hz, 1H), 4.52 (dd, J = 10.34, 1.95 Hz, 1H), 4.07 (m, 1H),
3.95 (m, 1H), 3.75 (s, 3H), 3.76 (q, J = 7.3 Hz, 2H), 3.60 (s, 3H), 3.53 (s, 3H), 3.50 (s, 3H),
3.27 (s, 3H), 2.80 (d, J = 2.57 Hz, 1H), 2.79 (d, J = 3.06 Hz, 1H), 2.31 (m, 2H), 1.79 (m,
1H), 1.71 (d, J = 7.24, 3H), 1.68 (t, J = 7.58, 3H), 1.43 (s, 9H), 1.42 (s, 9H), −1.61 (s, 1H),
−1.91 (s, 1H). The 131- β-alanyl-aspartylchlorin e6 di(tert)butyl dimethyl ester (45 mg,
0.048 mmol) was dissolved in 2 ml of dry CH2Cl2 in a ice bath under argon. Thioanisole
(0.004 ml) and 2 ml of TFA were added and the reaction mixture was stirred overnight
before being evaporated several times with diethyl ether to remove residual TFA. The
resulting precipitate was washed several times with diethyl ether to remove more residual
thioanisole. The precipitate was dissolved in CH2Cl2 and washed three times with H2O and
once with 10% NaHCO3 to remove TFA. The organic layer was dried over anhydrous
Na2SO4 and the solvent was evaporated to give 38 mg, 0.046 mmol; 97% yield of 131aspartylchlorin e6 DME (C43H50N6O10). UV-Vis (acetone): λmax (ε/M−1cm−1) 663
(77,125), 607 (3,621), 528 (1,831), 500 (17,200), 399 (237,100); 1H NMR [(CD3)2CO, 400
MHz]: δ 9.72 (s, 1H), 9.70 (s, 1H), 9.10 (s, 1H), 8.20 (dd, J = 11.58, 17.85 Hz, 1H), 8.11 (br
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t, J = 5.66 Hz, 1H), 7.64 (br d, J = 8.11 Hz, 1H), 6.32 (d, J = 19.18 Hz, 1H), 6.10 (d, J =
12.94 Hz, 1H), 5.63 (d, J = 19.03 Hz, 1H), 5.37 (d, J = 19.09 Hz, 1H), 4.92 (dt, J = 8.14,
5.74 Hz, 1H), 4.66 (q, J = 7.22 Hz, 1H), 4.51 (dd, J = 10.34, 1.95 Hz, 1H), 4.07 (m, 1H),
3.95 (m, 1H), 3.74 (s, 3H), 3.75 (q, J = 7.3 Hz, 2H), 3.60 (s, 3H), 3.51 (s, 3H), 3.50 (s, 3H),
3.25 (s, 3H), 2.96 (d, J = 5.27 Hz, 1H), 2.69 (d, J = 3.06 Hz, 1H), 2.31 (m, 2H), 1.79 (m,
1H), 1.71 (d, J = 7.24, 3H), 1.66 (t, J = 7.58, 3H), −1.61 (s, 1H), −1.91 (s, 1H). HRMS
(MALDI-TOF) m/z 811.381 [M+H]+, calcd. for C43H51N6O10 811.367.
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131-Ethylenediaminylchlorin e6 DME (12)—Methyl pheophorbide a, (100 mg, 0.164
mmol) was dissolved in dry CHCl3 and stirred under argon for 10 min. 0.2 ml of
ethylenediamine was added to the solution and the mixture stirred for 24 h. The reaction was
monitored by spectrophotometry. The reaction mixture was evaporated and the residue was
dissolved in 2.5% MeOH/CH2Cl2 and then chromatographed on a short silica gel column
using the same mobile phase to remove by-products, and then the product was eluted using
50% MeOH/CH2Cl2 to afford 100 mg, 0.150 mmol: 91% yield of 131ethylenediaminylchlorin e6 DME (C38H46N6O5). 1H NMR [(CD3)2CO, 400 MHz]: δ 9.69
(s, 1H), 9.63 (s, 1H), 9.09 (s, 1H), 8.09 (dd, J = 17.78, 11.58 Hz, 1H), 8.07 (br s, 1H), 6.29
(d, J = 18.85 Hz, 1H), 6.02 (d, J = 11.87 Hz, 1H), 5.67 (d, J = 19.08 Hz, 1H), 5.39 (d, J =
19.11 Hz, 1H), 4.66 (q, J = 7.22 Hz, 1H), 4.51 (dd, J = 10.34, 1.95 Hz, 1H), 4.01 (m, 1H),
3.87 (m, 1H), 3.75 (s, 3H), 3.66 (q, J = 7.3 Hz, 2H), 3.61 (s, 3H), 3.50 (s, 3H), 3.45 (s, 3H),
3.20 (s, 3H), 2.71 (m, 1H), 2.31 (m, 2H), 1.95 (br m, 1H), 1.80 (m, 1H), 1.72 (d, J = 7.24,
3H), 1.64 (t, J = 7.58, 3H), −1.64 (s, 1H), −1.93 (s, 1H). 13C NMR [(CD3)2CO, 100 MHz] δ
173.1, 173.0, 169.2, 168.3, 167.7, 153.6, 149.1, 144.4, 138.1, 136.0, 135.3, 134.7, 133.9,
130.1, 129.8, 129.3, 120.9, 103.2, 100.7, 98.4, 93.9, 53.1, 51.4, 50.8, 50.2, 48.8, 41.2, 37.2,
30.7, 29.6, 22.6, 19.0, 17.2, 11.3, 11.0, 10.3. HRMS (MALDI-TOF) m/z 667.395 [M+H]+,
calcd. for C38H47N6O5 667.361.
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131-Ethylenediaminyl-lysylchlorin e6 DME (13)—(Boc)Lysine(Boc)OH (55 mg,
0.082 mmol) was dissolved in dry CH2Cl2 (10 ml) A mixture of HOBt (15 mg), TBTU (33
mg) and DIEA (0.025 ml) in DMF was added and then stirred for 1 h. 131Ethylenediaminylchlorin e6 DME (50 mg, 0.075 mmol) was added to the reaction mixture,
which was stirred overnight. The mixture was diluted with CH2Cl2 and then washed with
5% aqueous citric acid, followed by a wash with brine and water. It was dried over
anhydrous Na2SO4 and then evaporated. The residue was dissolved in 2.5% MeOH/CH2Cl2
and purified via silica gel column chromatography using the same mobile phase to afford 65
mg, 0.065 mmol; 78% yield of 131-ethylenediaminyl(Boc)lysyl(Boc)chlorin e6 DME
(C54H74N8O10). 1H NMR [(CD3)2CO, 400 MHz]: δ 9.54 (s, 1H), 9.53 (s, 1H), 9.07 (s, 1H),
8.14 (br s, 1H) 7.94 (dd, J = 17.78, 11.58 Hz, 1H), 7.78 (br s, 1H), 6.18 (d, J = 18.85 Hz,
1H), 6.16 (br s, 1H), 5.93 (d, J = 11.87 Hz, 1H), 5.89 (br s, 1H), 5.63 (d, J = 19.08 Hz, 1H),
5.39 (d, J = 19.11 Hz, 1H), 4.67 (q, J = 7.22 Hz, 1H), 4.52 (dd, J = 10.34, 1.95 Hz, 1H), 4.17
(m, 1H), 3.85 (m, 1H), 3.75 (s, 3H), 3.66 (m, 3H), 3.61 (s, 3H), 3.52 (br q, J = 7.14 Hz, 2H),
3.41 (s, 3H), 3.39 (s, 3H), 3.11 (s, 3H), 3.00 (m, 2H), 2.71 (m, 1H), 2.32 (m, 2H), 1.95 (br
m, 1H), 1.84 (m, 2H), 1.72 (d, J = 7.24, 3H), 1.67 (m, 1H), 1.59 (t, J = 7.58, 3H), 1.41 (m,
3H), 1.37 (s, 9H), 1.34 (s, 9H), −1.66 (s, 1H), −1.94 (s, 1H). The 131ethylenediaminyl(Boc)lysyl(Boc)-chlorin e6 DME (65 mg, 0.065 mmol) was dissolved in 3
ml of dry CH2Cl2 in a ice bath under argon. Thioanisole (0.003 ml) and 2 ml of TFA were
added and the reaction mixture was stirred overnight. The reaction mixture was evaporated
several times with diethyl ether to remove TFA. The resulting precipitate was washed
several times with diethyl ether to remove thioanisole. Then the precipitate was dissolved in
CH2Cl2 and washed three times with H2O and once with 10% NaHCO3 to remove TFA.
The organic layer was dried over anhydrous Na2SO4 and the solvent was evaporated to give
42 mg, 0.052 mmol; 81% yield of 131-ethylenediaminyl-lysylchlorin e6 DME
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(C44H58N8O6). UV-Vis (acetone): λmax (ε/M−1cm−1) 663 (76,420), 607 (1810), 527 (657),
500 (14,560), 399 (242,100); 1H NMR [(CD3)2CO, 400 MHz]: δ 9.76 (s, 1H), 9.69 (s, 1H),
9.10 (s, 1H), 8.29 (br s, 1H) 8.17 (dd, J = 17.78, 11.58 Hz, 1H), 7.86 (br s, 1H), 6.35 (d, J =
18.85 Hz, 1H), 6.07 (d, J = 11.87 Hz, 1H), 5.64 (d, J = 19.08 Hz, 1H), 5.40 (d, J = 19.11 Hz,
1H), 4.66 (q, J = 7.22 Hz, 1H), 4.52 (dd, J = 10.34, 1.95 Hz, 1H), 3.92 (m, 2H), 3.75 (br m,
5H), 3.74 (s, 3H), 3.60 (s, 3H), 3.53 (s, 3H), 3.49 (s, 3H), 3.26 (s, 3H), 2.96 (br t, 2H), 2.70
(m, 1H), 2.29 (m, 2H), 1.95 (br m, 1H), 1.84 (m, 2H), 1.72 (d, J = 7.24, 3H), 1.68 (t, J =
7.58, 3H), 1.45 (m, 2H), 1.31 (m, 2H) −1.60 (s, 1H), −1.89 (s, 1H). HRMS (MALDI-TOF)
m/z 795.492 [M+H]+, calcd. for C44H59N8O6 795.456.
2. Cell Studies
Human carcinoma HEp2 cells were maintained in a 50:50 mixture of DMEM:AMEM
(Invitrogen) supplemented with 5% FBS (Invitrogen), 1% Primocin antibiotic (Invitrogen)
in a humidified, 5% CO2 incubator at 37 °C. The cells were sub-cultured twice weekly to
maintain sub-confluent stocks. The 4th to 15th passage cells were used for all experiments.
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2.1. Time-Dependent Cellular Uptake—The HEp2 cells were plated at 7500 cells per
well in a Costar 96-well plate and allowed to grow for 48 h. Compound stock solutions were
prepared at 32 mM in DMSO and Cremophor (10% of Cremophor in DMSO). Further
dilution into the cells of the 96-well plate gave a final concentration of 10 µM with
maximum DMSO concentration of 1% and Cremophor concentration of 0.1%. For the
uptake test, the compounds were diluted to 20 µM (2× stock solution) and added to the 96well to give a final concentration of 10 µM at 0, 1, 2, 4, 8, 12 and 24 h interval. The uptake
was terminated by removing the loading medium and washing the wells with 200 µL PBS
buffer. Cells and compounds were then solubilized using 100 µL of 0.25% Triton X-100 in
PBS buffer. The compound concentration was measured using intrinsic fluorescence as
measured with a BMG FLUOstar plate reader equipped with a 355 nm excitation and a 650
nm emission filter. The cells were measured using a CyQuant Cell proliferation assay
(Invitrogen) as per manufacturer’s instructions, as previously reported.20,21,24
2.2. Dark Cytotoxicity—The HEp2 cells were plated as described above for the uptake
experiment. The compounds were diluted into media to give 400 µM solution
concentrations. Two-fold serial dilutions were then prepared from 400 to 50 µM, and the
cells were incubated for 18 h. The loading medium was removed and the cells were fed new
medium, followed by 20 µL CellTiter blue per 100 µL medium, and incubated for 4 h. Cell
toxicity was measured using Promega’s CellTiter Blue Viability Assay Kit as per
manufacturer’s instructions; untreated cells were considered 100% viable and cells treated
with 0.2% saponin as 0% viable, as previously reported.20,21,24
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2.3. Phototoxicity—The cells were prepared as described above with compound
concentration range from 6.25–100 µM. After loading overnight, the medium was replaced
with medium containing 50 mM HEPES pH 7.2. The cells were exposed to a 100 W halogen
lamp filtered through a 610 nm long pass filter to provide approximately 1 Jcm−2 light dose.
The cells were kept cool by filtering the IR radiation through 10 mm of water and placing
the culture in an ice-water bath. After exposure to light for 20 min, the plate was incubated
in the 37 °C, 5% CO2 incubator overnight. Cell viability was then measured as described
above using CellTiter blue Viability Assay Kit, as previously reported.20,21,24
2.4. Microscopy—The cells were incubated in a glass bottom 6-well plate (MatTek) and
allowed to grow for 48 h. The cells were then exposed to 10 µM of each compound for 18 h.
Organelle tracers were obtained from Invitrogen and used at the following concentrations:
LysoSensor Green 50 nM, MitoTracker Green 250 nM, ER Tracker Blue/white 100 nM, and
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BODIPY FL C5 ceramide 1 mM. After 30 min incubation in the 37 °C, 5% CO2 incubator,
both the media and the organelle tracers were removed and washed with PBS buffer for 3
times. Images were acquired using a Leica DMRXA microscope with 40× NA 0.8 dip
objective lens and DAPI, GFP and Texas Red filter cubes (Chroma Technologies).

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.

173, 152 and 131 regioisomers of “R”-substituted chlorin e6.
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Figure 2.

Energy minimized conformations in gas phase for chlorin e6 derivatives (a) [131 LysChlorin
e6TME]+, (b) 13, (c) 7b and (d) 3. Optimization by energy was carried out at HF/6-31G
level.
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Figure 3.
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Time-dependent uptake of chlorin e6 (5, black line) and its derivatives 173-LysChlorin
e6TME (3, brown line), 152-AspChlorin e6DME (7a, light blue line), 152-LysChlorin
e6TME (7b, red line), 152-AspPdChlorin e6DME (8a, green line), 152-LysPdChlorin e6TME
(8b, blue line), 131-AspChlorin e6DME (9, maroon line), 131-βAlaAspChlorin e6DME (11,
purple line) and 131-EDLysChlorin e6DME (13, pink line) at 10 µM by HEp2 cells.
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Figure 4.

Dark toxicity of chlorin e6 (5, black line) and its derivatives 173-LysChlorin e6TME (3,
brown line), 152-AspChlorin e6DME (7a, light blue line), 152-LysChlorin e6TME (7b, red
line), 152-AspPdChlorin e6DME (8a, green line), 152-LysPdChlorin e6TME (8b, blue line),
131-AspChlorin e6DME (9, maroon line), 131-βAlaAspChlorin e6DME (11, purple line) and
131-EDLysChlorin e6DME (13, pink line) toward HEp2 cells using 1 J/cm2 light dose and
the Cell Titer Blue assay.
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Figure 5.

Phototoxicity of chlorin e6 (5, black line) and its derivatives 173-LysChlorin e6TME (3,
brown line), 152-AspChlorin e6DME (7a, light blue line), 152-LysChlorin e6TME (7b, red
line), 152-AspPdChlorin e6DME (8a, green line), 152-LysPdChlorin e6TME (8b, blue line),
131-AspChlorin e6DME (9, maroon line), 131-βAlaAspChlorin e6DME (11, purple line) and
131-EDLysChlorin e6DME (13, pink line) toward HEp2 cells using 1 J/cm2 light dose and
the Cell Titer Blue assay.
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Figure 6.

Subcellular localization of conjugate 131 AspCe6DME (9) in HEp2 cells at 10 µM for 18 h
(a) phase contrast, (b) overlay of conjugate 9 compound and phase contrast, (c) ER tracker
Blue/White fluorescence (e) MitoTracker Green fluorescence, (g) BoDIPY Ceramide, (i)
LysoSensor Green fluorescence, and (d, f, h, j) overlays of organelle tracers with compound
fluorescence. Scale bar: 10 µm.

J Med Chem. Author manuscript; available in PMC 2012 November 10.

Waruna Jinadasa et al.

Page 23

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

Figure 7.

Subcellular localization of conjugate 131 β-Ala-AspCe6DME (11) in HEp2 cells at 10 µM
for 18 h (a) phase contrast, (b) overlay of conjugate 11 and phase contrast, (c) ER tracker
Blue/White fluorescence (e) MitoTracker Green fluorescence, (g) BoDIPY Ceramide, (i)
LysoSensor Green fluorescence, and (d, f, h, j) overlays of organelle tracers with compound
fluorescence. Scale bar: 10 µm.
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Figure 8.

Subcellular localization of conjugate 131 ED-LysCe6DME (13) in HEp2 cells at 10 µM for
18 h (a) phase contrast, (b) overlay of conjugate 11 and phase contrast, (c) ER tracker Blue/
White fluorescence (e) MitoTracker Green fluorescence, (g) BoDIPY Ceramide, (i)
LysoSensor Green fluorescence, and (d, f, h, j) overlays of organelle tracers with compound
fluorescence. Scale bar: 10 µm.
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Reaction conditions: a) TFA:H2O 4:1, 0 °C, 1 h, 90%; b) DCC, DMAP, H-Lys(Boc)OMe•HCl, DIEA, CH2CL2, rt, 14 h, 52%; c) NaOMe, THF, 0 °C, 4 h, 89%; d) TFA,
CH2Cl2, thioanisole, 0 °C to rt, 12 h, 72%; e) 5% H2SO4/MeOH, rt, 12 h, 96%; f) NaOMe,
THF, 0 °C, 4 h, 98%; g) 18 eq LiI, EtOH, reflux, 24 h, 21%; h) 5% H2SO4/MeOH, rt, 12 h,
99%.
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Scheme 2.
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Reaction conditions: a) DCC, DMAP, CH2Cl2, rt, 2 h; H-Asp(Boc)2•HCl or H-Lys(Boc)OMe•HCl, DIEA, CH2Cl2, rt, 14 h; b) CH2N2, CH2Cl2, 30 min; c) TFA, CH2Cl2,
thioanisole, 0 °C to rt, 12 h (7a: 45%, 7b: 77%); d) Pd(OAc)2, THF, 60 °C, 3 h (8a: 98%,
8b: 99%).
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Scheme 3.

Reaction conditions: a) L-Asp(OtBu)2•HCl, DIEA, CH2Cl2, HOBt, TBTU, DMF, rt, 14 h,
66%; b) TFA, CH2Cl2, thioanisole, 0 °C to rt, 12 h, 88%; c) β-Ala(OtBu)•HCl, DIEA,
CH2Cl2, HOBt, TBTU, DMF, rt, 12 h, 68%; d) TFA, CH2Cl2, thioanisole, 0 °C to rt, 12 h,
95% e) L-Asp(OtBu)2•HCl, DIEA, CH2Cl2, HOBt, TBTU, DMF, rt, 12 h, 87% f) TFA,
CH2Cl2, thioanisole, 0 °C to rt, 12 h, 97%.
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Scheme 4.

Reaction conditions: a) NH2C2H4NH2, CHCl3, rt, 24 h, 91%; b) (Boc)Lys(Boc)-OH, DIEA,
CH2Cl2, HOBt, TBTU, DMF, rt, 12 h, 78%; c) TFA, CH2Cl2, thioanisole, 0 °C to rt, 12 h,
81%.
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Cytotoxicity (HEp2 cells) for chlorin e6 and its derivatives using the Cell Titer Blue assay
Compound

Dark toxicity (IC50, µM)

Phototoxicity (IC50, µM)

Ratio

Chlorin e6 (5)

>400

20.8

>19.2

173-LysChlorin

e6TME (3)

>400

26.2

>15.3

152-AspChlorin

e6DME (7a)

373.1

4.0

93.4

152-LysChlorin

e6TME (7b)

>400

28.8

>13.9

152-AspPdChlorin

e6DME (8a)

324.8

16.7

19.4

152-LysPdChlorin

e6TME (8b)

>400

3.3

>121.2

e6DME (9)

284.6

0.61

466.6

383.9

0.82

468.2

268.4

1.34

200.3

131-AspChlorin

131-βAlaAspChlorin
131-EDLysChlorin

e6DME (11)

e6DME (13)
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Major (++) and minor (+) subcellular sites of localization for chlorin e6 and its derivatives in HEp2 cells
Compound

Lysosomes

ER

Golgi

Mitochondria

Chlorin e6 (5)

+

++

−

−

+

++

+

−

152-AspChlorin e6DME (7a)

++

++

−

+

152-LysChlorin e6TME (7b)

++

++

+

−

152-AspPdChlorin e6DME (8a)

++

+

++

−

152-LysPdChlorin e6TME (8b)

+

++

−

−

131-AspChlorin e6DME (9)

+

++

++

++

131-βAlaAspChlorin e6DME (11)

++

++

++

−

131-EDLysChlorin e6DME (13)

++

++

++

−

173-LysChlorin

e6TME (3)
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